OncologyImmuno-oncology PKPDTCE/BsAb

Zenocutuzumab PK and tumor-growth dynamics

Reference paper ↗

A translational PK/PD model coupling zenocutuzumab distribution and nonlinear clearance to concentration-dependent tumor-cell death and net tumor-volume dynamics.

Therapeutic
Zenocutuzumab
Modality
Bispecific antibody / T-cell engager
Target
ERBB3, HER3, HER2 / ERBB2
Disease
HER2/HER3-driven preclinical tumors and first-in-human translation
Model type
PKPD, TCE/BsAb

Complete model workspace

Checking workspace access…

Parameters
14
States
6
Equations
6
Derived outputs
12

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Human 360 mg every 3 weeks receptor occupancy

How does zenocutuzumab exposure translate into tumor-growth inhibition over time? Explore this intervention regimen through Central zenocutuzumab concentration, Peripheral zenocutuzumab concentration, Tumor volume, Drug-modified tumor growth, Cumulative exposure.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–504 hour; step 24

InputDefaultAvailable range
Systemic clearance0.0125 L/h0.00625–0.01875 L/h
Central distribution volume3.17 L1.585–4.755 L
Maximum elimination rate0.5 mg/h0.25–0.75 mg/h
Michaelis constant0.219 mg/L0.1095–0.3285 mg/L
Tumor-kill half-maximal concentration1.02e-5 mg/L5.10e-6–1.53e-5 mg/L

Expected readouts

Central zenocutuzumab concentration · Peripheral zenocutuzumab concentration · Tumor volume (millimeter**3) · Drug modified tumor growth (dimensionless) · Exposure (AUC) (mg*h/L)

Adjustable model parameters

This public explorer exposes 5 curated parameters. Sign in to edit all 14 declared model parameters.

More key parameters (1)

How the model represents the biology

A translational PK/PD model coupling zenocutuzumab distribution and nonlinear clearance to concentration-dependent tumor-cell death and net tumor-volume dynamics.

How does zenocutuzumab exposure change empirical tumor growth and death drives?Intravenous zenocutuzumab enters a central pool, exchanges with a peripheral pool, and undergoes linear and saturable elimination. Central concentration separately lowers a tumor-growth drive and raises a tumor-death drive, which together change tumor volume.BIOLOGY OVERVIEWHow does zenocutuzumab exposure change empirical tumor growth and death drives?IV zenocutuzumabDose to central compartmentCentral exposureZenocutuzumab concentrationPeripheral poolReversible distributionPK eliminationLinear and saturable lossGrowth driveExposure lowers tumor growthDeath driveExposure raises tumor lossTumor volumeNet empirical tumor responsePRIMARY READOUTSCentral zenocutuzumab concentrationCentral zenocutuzumab conc…Peripheral concentrationPeripheral concentrationTumor volumeTumor volumeGrowth effectGrowth effectCumulative exposureCumulative exposure

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: HER2/HER3 binding, receptor occupancy or signaling, immune-effector killing, and target-mediated clearance are not represented; tumor pharmacodynamics are empirical exposure effects.

Modeled relationships (7)
  • IV zenocutuzumab → Central exposure: IV input (flow)
  • Central exposure ↔ Peripheral pool: distribution (reversible exchange)
  • Central exposure → PK elimination: linear + saturable (loss)
  • Central exposure → Growth drive: inhibits growth (modulation)
  • Growth drive → Tumor volume: growth contribution (production)
  • Central exposure → Death drive: stimulates death (modulation)
  • Death drive → Tumor volume: tumor loss (loss)

Modeled relationships: IV zenocutuzumab to Central exposure: IV input (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Central exposure to PK elimination: linear + saturable (loss); Central exposure to Growth drive: inhibits growth (modulation); Growth drive to Tumor volume: growth contribution (production); Central exposure to Death drive: stimulates death (modulation); Death drive to Tumor volume: tumor loss (loss).

Primary readouts: Central zenocutuzumab concentration; Peripheral concentration; Tumor volume; Growth effect; Cumulative exposure.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID de_vries_2018_mcla128_zenocutuzumab_pkpd.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics